What is the official website of Novartis Brasil ?

The official website of Novartis Brasil is https://www.novartis.com.br/.

What is Novartis Brasil's cybersecurity risk score?

Novartis Brasil has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Brasil experienced?

According to Rankiteo, Novartis Brasil currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Brasil been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Brasil has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Brasil have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Brasil is not certified under SOC 2 Type 1.

Does Novartis Brasil have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Brasil does not hold a SOC 2 Type 2 certification.

Does Novartis Brasil comply with GDPR ?

According to Rankiteo, Novartis Brasil is not listed as GDPR compliant.

Does Novartis Brasil have PCI DSS certification ?

According to Rankiteo, Novartis Brasil does not currently maintain PCI DSS compliance.

Does Novartis Brasil comply with HIPAA ?

According to Rankiteo, Novartis Brasil is not compliant with HIPAA regulations.

Does Novartis Brasil have ISO 27001 certification ?

According to Rankiteo,Novartis Brasil is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Brasil operate in ?

Novartis Brasil operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Brasil have ?

Novartis Brasil employs approximately 346 people worldwide.

Does Novartis Brasil own any subsidiaries ?

Novartis Brasil presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Brasil have ?

Novartis Brasil's official LinkedIn profile has approximately 149,378 followers.

What is the NAICS classification code for Novartis Brasil ?

Novartis Brasil is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Brasil have a Crunchbase profile ?

No, Novartis Brasil does not have a profile on Crunchbase.

Does Novartis Brasil have a LinkedIn profile ?

Yes, Novartis Brasil maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartisbrasil.

How many cybersecurity incidents has Novartis Brasil experienced ?

As of October 7, 2026, Rankiteo reports that Novartis Brasil has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Brasil have ?

Novartis Brasil has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Brasil faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Brasil

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

Novartis Brasil Vendor Cyber Rating & Cyber Score

novartis.com.br

Add Your Compliance Badge

A Novartis está reimaginando a medicina para melhorar e estender a vida das pessoas. Como líder mundial em medicamentos, usamos ciência inovadora e tecnologias digitais para criar tratamentos transformadores em áreas médicas de grande impacto. Em nossa busca por novos medicamentos, estamos constantemente entre as principais empresas do mundo que mais investem em pesquisa e desenvolvimento. Os produtos Novartis atingem quase um bilhão de pessoas em todo o mundo e estamos descobrindo maneiras inovadoras de expandir o acesso aos nossos tratamentos mais recentes. Cerca de 125 000 pessoas de mais de 140 nacionalidades trabalham na Novartis em todo o mundo. Veja nossas regras de comunidade:

Novartis Brasil

Novartis Brasil CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Brasil

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Brasil in 2026.

Incident History - Novartis Brasil (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Brasil Subsidiaries

Novartis Brasil

Pharmaceutical Manufacturing

Website: https://www.novartis.com.br/

Company Size: 346

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Brasil Similar Companies

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Loading…

NEWS

Novartis Brasil CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 16, 2024 07:00 AM

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Beatriz Silveira: Prior to this, Beatriz was the director and head of technology for APAC, EMEA, and Europe regions at Citi,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-97626

SUMMARY

Requesting a user or organization profile page (`GET /{username}`) with an `Accept: application/rss+xml` or `Accept: application/atom+xml` header returned the owner's activity feed without the visibility check that the profile page and the `.rss` and `.atom` routes apply. Anonymous users, restricted users and non-members could confirm the existence of limited or private users and private organizations and read their profile details and public activity, also when `[other] ENABLE_FEED` was disabled. Activity in private repositories was not included.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-97208

SUMMARY

The Gitea API endpoint for creating push mirrors (`POST /api/v1/repos/{owner}/{repo}/push_mirrors`) checked only whether mirroring was enabled and not the `[mirror] DISABLE_NEW_PUSH` setting that the web interface enforces. A repository administrator could therefore create new push mirrors on instances where the site administrator had disabled them. A push mirror pushes all refs of the repository to a remote chosen by the caller, on each commit or on a schedule.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-96594

SUMMARY

The Gitea API endpoint `GET /api/v1/repos/{owner}/{repo}/media/{filepath}` wrote files of up to 1 KiB that are stored directly in Git, not in LFS, to the response without the content type and disposition headers Gitea uses for user content. An HTML file committed to a repository was therefore rendered by the browser on the Gitea origin. A user who can push to a repository could run JavaScript in the session of a victim who opens the media URL and act with the victim's permissions.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-89182

SUMMARY

With `[repository] FORCE_PRIVATE = true`, Gitea creates new repositories as private, but the post-receive hook still applied the `repo.private=false` push option to an empty repository created by push. Any user who can create repositories could make their new repository public in violation of the instance policy. The default configuration is not affected.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-86684

SUMMARY

The Gitea push mirror API checked whether the repository owner, instead of the requesting user, may use local file system paths. On instances with `[security] IMPORT_LOCAL_PATHS = true`, a repository administrator who is not allowed to import local paths could add a push mirror to a local path on the server when the repository owner has that permission. Gitea then pushed the repository's refs into an existing Git repository at that path with the permissions of the Gitea process.

Published

Date2026-10-06

Updated

Date2026-10-06

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Brasil Vendor Cyber Rating & Cyber Score

Novartis Brasil A.I CyberSecurity Scoring

Novartis Brasil CyberSecurity News & History

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Brasil (X = Date, Y = Severity)

Novartis Brasil Subsidiaries

Novartis Brasil

Novartis Brasil Similar Companies

Alkem Laboratories Ltd.

Grifols

UCB

Sanofi

Hikma Pharmaceuticals

Torrent Pharmaceuticals Ltd

Novartis

MACLEODS PHARMACEUTICALS LTD.

MENARINI Group

Novartis Brasil CyberSecurity News

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Brasil CyberSecurity News & History

Novartis Brasil Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Brasil

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Brasil vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Brasil (X = Date, Y = Severity)

Novartis Brasil Subsidiaries

Novartis Brasil

Novartis Brasil Similar Companies

Alkem Laboratories Ltd.

Grifols

UCB

Sanofi

Hikma Pharmaceuticals

Torrent Pharmaceuticals Ltd

Novartis

MACLEODS PHARMACEUTICALS LTD.

MENARINI Group

Novartis Brasil CyberSecurity News

Novartis appoints Beatriz Silveira as Global Security Regional Head for APAC

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo